Thursday - March 12, 2026

Severe Asthma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Severe Asthma pipeline constitutes 40+ key companies continuously working towards developing 50+ Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Allergic Rhinitis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Inmunotek, Iltoo Pharma, Advagene Biopharma, AOBiome LLC, Emergo Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Projecting the Global Orthotic Devices Market Size to Expand at a 5.41% CAGR Through 2034, DelveInsight Analysis

Orthotic Devices Market Insights, Competitive Landscape, and Market Forecast – 2034” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.   As per DelveInsight’s assessment, The orthotic devices market is mainly fueled by … Continue reading

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics

The Key Myelofibrosis Companies: in the market include – Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others .   DelveInsight’s … Continue reading